Search Within

Sarcoma Service

Formats
  1. Journal Article (455)
  2. Meeting Abstract (431)
  3. Review (29)
  4. Editorial (9)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (953)
  2. Solid Tumor Oncology Division (953)
  3. GSK Faculty (343)
  4. Tow Center for Developmental Oncology (TCDO) (310)
  5. Hematologic Malignancies, Division of (295)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. William Tap (382)
  2. Sandra D'Angelo (256)
  3. Mrinal Gounder (232)
  4. Ping Chi (177)
  5. Mark Dickson (173)
  6. Cristina Antonescu (138)

More People

Years
  1. 2025 (44)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (274)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (61)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (28)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (288)
  2. American Association for Cancer Research (108)
  3. Oxford University Press (92)
  4. Elsevier Inc. (57)
  5. Nature Publishing Group (42)
  6. Springer (40)

More Publishers

Results (953)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
    Review

    Somaiah, N.; Tap, W.
    Cancer Treatment Reviews (2024)

    Fulltext@MSK | Save
  • Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
    Meeting Abstract

    Chen, T. W. W.; Sanfilippo, R.; Jones, R. L.; Schuetze, S. M.; Sebio Garcia, A.; Alvarez, R. M.; Bui, N.; Ahn, J. H.; Loong, H. H. F.; Yen, C. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Immune-related adverse events after immune checkpoint blockade-based therapy are associated with improved survival in advanced sarcomas
    Journal Article

    Rosenbaum, E.; Seier, K.; Bradic, M.; Kelly, C.; Movva, S.; Nacev, B. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Cancer Research Communications (2023)

    Fulltext@MSK | Save
  • High-grade undifferentiated pleomorphic sarcoma masquerading as acquired lymphangioma circumscriptum
    Miscellaneous

    Rambhia, P. H.; D’angelo, S. P.; Shah, P. R.
    SKIN: Journal of Cutaneous Medicine (2023)

    Fulltext@MSK | Save
  • Quality of life and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors: analyses from INVICTUS
    Meeting Abstract

    Bauer, S.; Heinrich, M. C.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
    Meeting Abstract

    Jones, R. L.; Sanfilippo, R.; Schuetze, S. M.; Sebio, A.; Alvarez, R. M.; Bui, N.; Wagner, A. J.; Chawla, S. P.; Chen, T. W. W.; Pink, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
    Meeting Abstract

    Kasper, B.; Gounder, M.; Chugh, R.; Agulnik, M.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; Gordon, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase I trial of NB003, a potent and selective KIT/PDGFRa inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Chi, P.; Shen, L.; Li, J.; Zhang, J.; Hu, K.; Zhang, L.; Xu, Y.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
    Meeting Abstract

    Schoeffski, P.; Lorusso, P.; Yamamoto, N.; Lugowska, I.; Garcia, V. M.; Lauer, U.; Hu, C.; Jayadeva, G.; Lahmar, M.; Gounder, M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
    Meeting Abstract

    DeMatteo, R.; Sgroe, E.; Merrill, M. B.; Gounder, M.; Liu, D.
    Annals of Oncology (2023)

    Fulltext@MSK | Save